We are live on ! Find out more
AC

Armistice Capital Portfolio holdings

AUM $5.62B
1-Year Est. Return 36.06%
This Fund
S&P 500
This Quarter Est. Return
1 Year Est. Return
+36.06%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$5.62B
AUM Growth
-$2.78B
Cap. Flow
Cap. Flow %
Top 10 Hldgs %
Holding
465
New
Increased
Reduced
Closed

Top Buys

Rank Stock Value
1
+$44.1M
2
+$36.9M
3
+$33.9M
4
MDLN
Medline Inc
MDLN
+$22.4M
5
META icon
Meta Platforms (Facebook)
META
+$20.9M

Top Sells

Rank Stock Value
1
+$70.6M
2
+$56.5M
3
+$53.6M
4
GEHC icon
GE HealthCare
GEHC
+$53.1M
5
PTCT icon
PTC Therapeutics
PTCT
+$51.5M

Sector Composition

Rank Sector Weight
1 Healthcare 38.27%
2 Technology 7.29%
3 Consumer Discretionary 4.25%
4 Communication Services 1.58%
5 Consumer Staples 1.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$781B
$1.37B 24.28%
2,100,000
-900,000
IWM icon
2
PUT
iShares Russell 2000 ETF
IWM
$81.2B
$868M 15.43%
3,500,000
-4,600,000
TVTX icon
3
Travere Therapeutics
TVTX
$5.16B
$146M 2.59%
4,897,417
+1,133,526
PTCT icon
4
PTC Therapeutics
PTCT
$6.47B
$141M 2.51%
2,074,449
-727,420
MDGL icon
5
Madrigal Pharmaceuticals
MDGL
$12.4B
$139M 2.46%
264,583
-1,122
CYTK icon
6
CALL
Cytokinetics
CYTK
$10.7B
$112M 1.99%
1,700,000
+200,000
AGIO icon
7
CALL
Agios Pharmaceuticals
AGIO
$2.38B
$108M 1.93%
3,200,000
+200,000
SUPN icon
8
Supernus Pharmaceuticals
SUPN
$2.75B
$98M 1.74%
1,895,347
-868,653
NBIX icon
9
Neurocrine Biosciences
NBIX
$17.4B
$95.4M 1.7%
724,000
-96,240
AGIO icon
10
Agios Pharmaceuticals
AGIO
$2.38B
$91.9M 1.63%
2,716,000
-320,000
IMVT icon
11
Immunovant
IMVT
$8.2B
$88.6M 1.57%
3,564,916
-2,182,239
FRPT icon
12
Freshpet
FRPT
$2.8B
$64.5M 1.15%
1,093,307
-202,693
INCY icon
13
Incyte
INCY
$23.1B
$61.8M 1.1%
656,817
-441,285
DYN icon
14
Dyne Therapeutics
DYN
$3.88B
$57.6M 1.02%
3,175,110
-74,598
AMZN icon
15
Amazon
AMZN
$2.69T
$54.6M 0.97%
262,137
-105,496
IRWD icon
16
Ironwood Pharmaceuticals
IRWD
$634M
$52.7M 0.94%
15,028,000
-997,000
CYTK icon
17
Cytokinetics
CYTK
$10.7B
$50.4M 0.9%
764,538
-228,228
IMVT icon
18
CALL
Immunovant
IMVT
$8.2B
$47.2M 0.84%
1,900,000
+1,150,000
HRMY icon
19
Harmony Biosciences
HRMY
$1.94B
$45.5M 0.81%
1,624,000
+1,124,000
TMO icon
20
Thermo Fisher Scientific
TMO
$196B
$45M 0.8%
91,491
+28,653
NKTR icon
21
Nektar Therapeutics
NKTR
$2.19B
$41.6M 0.74%
578,000
-18,000
UNH icon
22
UnitedHealth
UNH
$383B
$40M 0.71%
+148,000
UBER icon
23
Uber
UBER
$147B
$37.3M 0.66%
518,760
+236,026
IMCR icon
24
Immunocore
IMCR
$1.73B
$35.8M 0.64%
1,188,000
+90,000
XRAY icon
25
Dentsply Sirona
XRAY
$2.7B
$34.8M 0.62%
3,000,000
-4,298,000
1
2 3 4 5

Similar funds

CRC
Curi RMB Capital Chicago, Illinois $5.62B AUM 18.93% 1-Year Est. Return
RMDI
R.M. Davis Inc Portland, Maine $5.63B AUM 21.26% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
DWM
Diversify Wealth Management Sandy, Utah $5.61B AUM 19.63% 1-Year Est. Return
DCP
DSM Capital Partners Palm Beach Gardens, Florida $5.66B AUM 27.45% 1-Year Est. Return
EW
Evoke Wealth Los Angeles, California $5.57B AUM 23.85% 1-Year Est. Return
AIM
Alphinity Investment Management Sydney, Australia $5.68B AUM 26.72% 1-Year Est. Return
O
Ossiam Paris, France $5.69B AUM 30.95% 1-Year Est. Return

Armistice Capital's Q1 2026 Portfolio in Review

As of Q1 2026, Armistice Capital held 465 positions worth $5.62B, down 33% from $8.4B the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Armistice Capital withdrew a net $2.47B in Q1 2026, closing 204 positions and reducing 84 holdings. Its most notable exit was argenx, an estimated $48.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 38% of assets, up from 33% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, Armistice Capital opened a new position in UnitedHealth worth $40M.

  • Armistice Capital's largest Q1 2026 buy was UnitedHealth: 148,000 shares worth $40M.
  • Armistice Capital added most to Harmony Biosciences in Q1 2026, an estimated $36.9M increase.
  • Armistice Capital's biggest Q1 2026 reduction was Kenvue, cutting an estimated $70.6M.
  • Armistice Capital fully exited argenx in Q1 2026, selling an estimated $48.8M.
  • Armistice Capital's ten largest holdings make up 56% of its $5.62B portfolio in Q1 2026.
  • Armistice Capital opened 101 new positions and closed 204 in Q1 2026.
  • Armistice Capital's portfolio value fell 33% quarter-over-quarter to $5.62B.

Based on Armistice Capital's 13F filing for Q1 2026, filed 15 May 2026.